Perbaikan Kualitas Hidup pada Pasien Solitary Fibrous Tumor Mediastinum: Perspektif Kemoterapi Paliatif
[Improvement of Quality of Life in Mediastinal Solitary Fibrous Tumor: Paliative Chemoteraphy Perspective]
Downloads
Background: Mediastinal solitary fibrous tumor (SFT) is a rare spindle cell neoplasm. Approximately 1 to 8% of these intrathoracic tumors have been reported to occur in the mediastinum. The chief complaints of mediastinal SFT are cough, shortness of breath or chest pain, or may occur as asymptomatic incidental mass. The treatment of choice for SFT is extensive surgical resection. However, when the tumor cannot be removed surgically or when metastases occur, chemotherapy and or radiotherapy can be proposed as palliative treatments. Case: A 19-year-old man with chief complaint of left chest pain and referred to his left back. The complaint is accompanied by cough without sputum and hoarseness. In thoracic CT scan with contrast, we found giant cystic mass suspect malignancy around 17x12x18 cm in left hemithorax, a minimal pericardial effusion, and left pleural effusion. There were positive tumor cell cytoplasm results in vimentin, negative tumor cell cytoplasm in CK, positive tumor cell membrane in CD99, cytoplasm of focal positive tumor cells in EMA, and negative tumor cells in CD34 which supported a solitary fibrous tumor in the immunohistochemical staining analysis. Doxorubicin-Ifosfamide regimen was the choice of chemotherapy palliative treatment in the case report. In the CT scan evaluation of thorax with contrast, we found stable disease (RECIST criteria) with improve quality of life (QOL) according to EQ-5D-3L, 11111 indicated no problems in 5 dimensions, such as mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Conclusion: Mediastinal SFT is a rare spindle cell neoplasm, and the diagnosis requires pathological and immunohistochemical staining analysis. Doxorubicin-Ifosfamide regimen can be proposed as a palliative chemotherapy regimen, which has been shown to improve QOL patients in Mediastinal SFT. EQ-5D is a simple tool that can be used to measure QOL such as mobility, self-care, usual activities, pain or discomfort, and anxiety or depression.
Vanfleteren LEGW, Peulen HMU, Creytens DHK V, et al. Complete Metabolic Remission of an Irresectable Mediastinal Solitary Fibrous Tumour with Concurrent Chemoradiation. Thorax 2009; 64: 822–823.
Künzel J, Hainz M, Ziebart T, et al. Head and Neck Solitary Fibrous Tumors: A Rare and Challenging Entity. Eur Arch Oto-Rhino-Laryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology - Head Neck Surg 2016; 273: 1589–1598.
Park MS, Ravi V, Conley A, et al. The Role of Chemotherapy in Advanced Solitary Fibrous Tumors: A Retrospective Analysis. Clin Sarcoma Res 2013; 3: 7.
Soomro NH, Pervaiz S, Hussain A, et al. Solitary Fibrous Tumor of the Mediastinum: A Rare Tumor at a Rare Site.
De Raet J, Sacré R, Hoorens A, et al. Malignant Giant Solitary Fibrous Tumor of the Mediastinum. J Thorac Oncol 2008; 3: 1068–1070.
Webb AJ, Yassin AS, Saeed A, et al. Mediastinal Solitary Fibrous Tumor Diagnosed by Endobronchial Ultrasound-Directed Biopsy. Am J Case Rep 2017; 18: 549–552.
Song S, Li P. Giant Solitary Fibrous Tumor of Posterior Mediastinum: A Case Report. J Nucl Med Radiat Ther; 07. Epub ahead of print 1 January 2016. DOI: 10.4172/2155-9619.1000276.
Gannon BR, O'Hara CD, Reid K, et al. Solitary Fibrous Tumor of the Anterior Mediastinum: A Rare Extrapleural Neoplasm. Tumori 2007; 93: 508–510.
Chick JFB, Chauhan NR, Madan R. Solitary Fibrous Tumors of the Thorax: Nomenclature, Epidemiology, Radiologic and Pathologic Findings, Differential Diagnoses, and Management. AJR Am J Roentgenol 2013; 200: W238-48.
Levard A, Derbel O, Méeus P, et al. Outcome of Patients with Advanced Solitary Fibrous Tumors: The Centre Léon Bérard Experience. BMC Cancer 2013; 13: 109.
Lu C, Ge D. A Large Solitary Fibrous Tumor of the Mediastinum. Chinese J Clin Oncol 2006; 3: 452–454.
Ginat DT, Bokhari A, Bhatt S, et al. Imaging Features of Solitary Fibrous Tumors. AJR Am J Roentgenol 2011; 196: 487–495.
Saynak M, Veeramachaneni NK, Hubbs JL, et al. Solitary Fibrous Tumors of Chest: Another Look with the Oncologic Perspective. Balkan Med J 2017; 34: 188–199.
Magdeleinat P, Alifano M, Petino A, et al. Solitary Fibrous Tumors of the Pleura: Clinical Characteristics, Surgical Treatment and Outcome. Eur J Cardio-Thoracic Surg Off J Eur Assoc Cardio-Thoracic Surg 2002; 21: 1087–1093.
Alawi F, Stratton D, Freedman PD. Solitary Fibrous Tumor of the Oral Soft Tissues: A Clinicopathologic and Immunohistochemical Study of 16 Cases. Am J Surg Pathol 2001; 25: 900–910.
Yokoi T, Tsuzuki T, Yatabe Y, et al. Solitary Fibrous Tumour: Significance of P53 and CD34 Immunoreactivity in Its Malignant Transformation. Histopathology 1998; 32: 423–432.
Bajwah S, Namisango E, Janssen DJA, et al. The Need for Palliative Care. ERS Monogr 2016; 2016: 21–34.
Reenen M van, Oppe M, Boye KS, et al. EQ-5D-3L User Guide: Basic Information on How to Use the EQ-5D-3L Instrument. Rotterdam, https://euroqol.org/wp-content/uploads/2019/10/EQ-5D-3L-User-Guide_version-6.0.pdf (2018).
Copyright (c) 2020 Aryo Dirgantara Putra, Winarinani Koesoemoprodjo
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.